From Name:
From Email:
To Name:
To Email:

Optional Message:


Novo, Sanofi go head to head as FDA clears new diabetes drugs

from Reuters

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market. Novo's Xultophy and Sanofi's Soliqua both combine a long-lasting insulin with a so-called GLP-1 medicine that stimulates insulin production in the pancreas. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063